![](/media/0npfuwgv/bild-a-rsredovisning-2020.jpg?anchor=center&mode=crop&width=10&height=5&rnd=132609547006430000)
JULY 17, 2024
Orexo Q2 2024 Interim Report
JULY 17, 2024
Orexo Q2 2024 Interim Report
JULY 16, 2024
Orexo shares new information on OX124, a high-dose naloxone rescue medication in development for opioid overdose
JULY 10, 2024
Orexo AB´s sustainability work ranked among top 5% by EcoVadis
A commercial stage pharmaceutical company with three revenue generating pharmaceutical products
AmorphOX® - a world-class powder-based drug delivery technology, leading to a new wave of a both small and large molecule pharmaceuticals.
Development pipeline targeting large medical needs
Read all documents related to the refinancing of the existing bond - MARCH 2024